Recently Closed Out Studies

04/14-Current               Enrollment Closed
Sponsor: ViiV Healthcare  Protocol: GSK200056
                                    Title: A Phase IIb Study Evaluating a Long-Acting Intramuscular Regimen of GSK 1265744
plus TMC278 For The Maintenance of Virologic Suppression Following an Induction of Virologic Suppression on an Oral regimen of GSKI 126 plus Abacavir/Lamivudine in HIV-1 infected Antiretroviral Therapy-Naïve Adult Subjects.
04/14-Current               Enrollment Open
                                    Sponsor: ViiV Healthcare  Protocol: GSK 201147
Title: a Phase IIIb, randomized, open-label study of the safety, efficacy, and tolerability of switching to fixed-dose combination of abacavir/dolutegravir/lamivudine from current antiretroviral regimen compared with continuation of the current antiretroviral regimen in HIV-1 infected adults who are virologically suppressed.
03/14-Current               Enrollment Closed
                                    Sponsor: Gilead Sciences, Inc. Protocol: GS-US-311-1089
                                    Title: A Phase 3, Randomized, Double-Blind, Switch Study to Evaluate F/TAF/ in HIV-1
                                    Positive Subjects who are Virologically Suppressed on Regimens containing FTC/TDF
02/14-Current               Enrollment Closed
                                    Sponsor: Gilead Sciences, Inc.    Protocol: GS-US-292-1249
Title: A Phase 3b Open-label Study of the Efficacy and Safety of
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1/Hepatitis B Co-infected Adults
01/14-Current               Enrollment Closed
                                    Sponsor: Bristol-Myers Squibb   Protocol: AI444-216
Title: A Phase 3 Evaluation of Daclatasvir Plus Sofosbuvir in Treatment-naïve and Treatment-Experienced Chronic Hepatitis C (Genotype 1, 2, 3, 4, 5, or 6) Subjects Coinfected with Human Immunodeficiency Virus (HIV)
08/13-Current               Enrollment Closed
                                    Sponsor: Gilead            Sciences, Inc.    Protocol: GS-US-292-0119
Title: A Phase 3 Open-Label Study to Evaluate Switching from Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) plus Darunavir (DRV) in Treatment-Experienced HIV-1 Positive Adults.
08/13-Current               Enrollment Open
                                    Sponsor: Gilead            Sciences, Inc.    Protocol: GS-US-292-0117
Title: A Phase 3, Two-Part Study to Evaluate the Efficacy ofTenofovir Alafenamide versus Placebo Added to a FailingRegimen Followed by Treatment with
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults
07/13-Current               Enrollment Open
                                    Sponsor: ViiV Healthcare           Protocol: ING117172
Title: A Phase IIIb, randomized, open-label study of the safety and efficacy of dolutegravir/abacavir/lamivudine ounce daily compared to Atazanavir and ritonavir plus tenofovir/Emtricitabine once daily in HIV-1 infected antiretroviral therapy naïve women
04/13-Current               Enrollment Closed
                                    Sponsor:  AbbVie          Protocol: M14-002
Title: A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naïve Adults with Genotype 1a Chronic Hepatitis C Virus (HCV) Infection (PEARL-IV)
04/13-Current               Enrollment Closed
                                    Sponsor:  Gilead Sciences, Inc.  Protocol:  GS-US-292-0109
Title:  A Phase 3, Open-Label Study to Evaluate Switching from a TDF-Containing Combination Regiment to a TAF-Containing Combination Single Tablet Regimen (STR) in Virologically-Suppressed, HIV-1 Positive Subjects
04/13-Current               Enrollment Closed
                                    Sponsor:  Gilead Sciences, Inc.  Protocol:  GS-US-292-0112
Title:  A Phase 3 Open-label Safety Study of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1 Positive Patients with Mild to Moderate Renal Impairment
03/13-Current               Enrollment Closed
                                    Sponsor:  Gilead Sciences, Inc.  Protocol:  GS-US-292-0111
Title:  A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide versus Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment – Naïve Adults
01/13-Current               Enrollment Closed
                                    Sponsor:  Gilead Sciences, Inc.  Protocol:  GS-US-292-0104
Title:  A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide versus Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment – Naïve Adults
01/13-06/14                   Study Closed
                                    Sponsor:  GSK  Protocol:  ING114916
Title:  A GSK1349572 Open Label Protocol for HIV-infected, Adult Patients with Integrase Resistance
11/12-Current               Enrollment Closed
                                    Sponsor:  Abbott Laboratories Protocol:  M13-102
Title:  A Follow-up Study to Assess Resistance and Durability of Response to Abbott Direct-Acting Antiviral Agent (DAA) Therapy in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection
11/12-08/14                   Study Closed
                                    Sponsor: Boehringer Ingelheim   Protocol: 1241.2
Title: A Phase III, Randomised, Partially Double-Blind and Placebo-Controlled Study of DI 207127 in Combination with Faldaprevir and Ribavirin in Treatment-Naïve Patients with Chronic Genotype 1 HCV Infection.
11/12-Current               Enrollment Closed
                                    Sponsor: Merck & Co., Inc. Protocol: MK 1439-007
Title: Multicenter, Double-Blind, Randomized, 2-Part, Dose Ranging Study to Compare the Safety, and Antiretroviral Activity of MK-1439 Plus Truvada Versus Efavirenz Plus Truvada in Antiretroviral Treatment-Naïve, HIV-1 Infected Patients
10/12-Current               Enrollment Closed
                                    Sponsor: Abbott Laboratories     Protocol: M11-646
Title: A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 C o-administered with Ribavirin (RBV) in Treatment-Naïve Adults with Genotype 1 Chronic Hepatitis C Virus (HCV) Infections (SAPPHIRE-1)
10/12-Current               Enrollment Closed
                                    Sponsor: Gilead Sciences           Protocol: GS-GS-236-0128
Title: A Randomized, Double-blind Phase 3B Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 infected, Antiretroviral Treatment-Naïve Women
09/12-03/2013               Study Closed
                                    Sponsor: Cerexa            Protocol: P903-27
Title: A Multicenter, Retrospective Cohort Study to Characterize the Use of Teflaro in the Treatment of Patients with Acute Bacterial Skin and Skin Structure Infection or Community-acquired Bacterial Pneumonia (CAPTURE)
08/12-Current               Enrollment Open
                                    Sponsor: Cubist Pharmaceuticals, Inc.     Protocol: LCD-CDAD-11-06
Title: A Randomized, Double-Blinded, Active-Controlled Study of Cb-183,315 in Patients with Clostridium Difficile Associated Diarrhea
07/12-Current               Enrollment Closed
                                    Sponsor: GlaxoSmithKline         Protocol: LAI116482
Title: A Phase IIb, dose ranging study of oral GSK 1265744 in combination with nucleoside reverse transcriptase inhibitors for induction of HIV-1 virologic suppression followed by an evaluation of maintenance of Virologic suppression when oral GSK 1265744 is combined with oral rilpivirine in HIV-1 infected, antiretroviral therapy naïve adult subjects (LATTE)
03/12-01/14                   Study Closed
                                    Sponsor:  GlaxoSmithKline/ViiV Protocol:  ING116529
Title:  A Phase III Randomized, Double-blind Study to Demonstrate the Antiviral Activity of Dolutegravir (DTG) 50 mg Twice Daily Versus Placebo Both Co-Administered with a Failing Antiretroviral Regimen over Seven Days, Followed by an Open-Label Phase with All Subjects Receiving DTG 50 mg Twice Daily co-administered with an Optimised Background Regimen (OBR) in HIV-1 Infected, Integrase Inhibitor Therapy-Experienced and Resistant, Adults  (VIKING4)
03/12-Current               Enrollment Closed
                                    Sponsor:  Abbott Laboratories  Protocol:  M13-101
Title:  An Open-Label Study to Evaluate the Safety, Antiviral Activity and Pharmacokinetics of Direct-Acting Antiviral Agent (DAA) Treatment in Combination with Peginterferon α-2a and Ribavirin (pegIFN/RBV) in Chronic Hepatitis C Virus (HCV) Infected Subjects Who Have Experienced Virologic Failure in a Previous Abbott DAA Combination Study.
03/12-05/12                   Study Closed
                                    Sponsor:  Gilead Sciences/Pharmassett  Protocol:  P7977-1231
Title:  A Phase 3, Multicenter, Randomized, Active-Controlled Study to Investigate the Safety and Efficacy of PSI-7977 and Ribavirin for 12 Weeks Compared to Pegylated Interferon and Ribavirin for 24 Weeks in Treatment-Naïve Patients with Chronic Genotype 2 or 3 HCV Infection (FISSION).
02/12-Current               Enrollment Closed
                                    Sponsor:  Gilead Sciences Protocol:  GS-US-236-0121
Title:  A Phase 3b Randomized, Open-Label Study to Evaluate Switching from Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) plus Emtricitabine (FTC) and Tenofovir DF (TDF) to the Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (EVG/COBI/FTC/TDF) in Virologically-Suppressed, HIV-1 Infected Patients.
02/12-05/13                   Study Closed
                                    Sponsor:  Gilead Sciences Protocol:  GS-US-236-0115
Title:  A Phase 3b Randomized, Open-Label Study to Evaluate Switching from Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI/r) plus Emtricitabine/Tenofovir Fixed-Dose Combination (FTC/TDF) to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (EVG/COBI/FTC/TDF) in Virologically-Suppressed, HIV-1 Infected Patients.
09/11-05/13                   Study Closed
                                    Sponsor:  KOWA Research Institute Protocol:  NK-104-4.05US
Title:  A 12-Week, Randomized, Double-Blind, Active- Controlled, Parallel-Group Study Comparing Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV-Infected Subjects with Dyslipidemia, followed by a 40-Week Safety Extension Study
09/11-Current               Enrollment Closed
                                    Sponsor:  Gilead Sciences Protocol:  GS-US-216-0130
Title:  A Phase 3b, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir Plus Two Fully Active Nucleoside Reverse Transcriptase Inhibitors in HIV-1 Infected, Antiretroviral Treatment-Naïve and Treatment-Experienced Adults with No Darunavir Resistance-associated Mutations
09/11-05/12                   Study Closed
                                    Sponsor:  GlaxoSmithKline/ViiV  Protocol:  EPI40670 / WWE115682
Title:  Observational Drug Exposure Registry for Long-Term Follow-Up of Subjects Exposed to GSK2248761
07/11-10/13                   Study Closed
                                    Sponsor:  Abbott Laboratories  Protocol:  M11-652
Title:  A Randomized, Open-Label, Multicenter Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics, of ABT-450 with Ritonavir (ABT-450/r) in Combination with ABT-267 and/or ABT-333 With and Without Ribavirin  (RBV) for 8, 12 or 24 Weeks in Treatment-Naïve and Null Responder Subjects with Genotype 1 Chronic Hepatitis C Virus Infection
06/11-Current               Enrollment on Hold
                                    Sponsor:  VGTI  Protocol:  N/A
Title:  Therapeutic and Natural Control of HIV Infection
06/11-01/14                   Study Closed
                                    Sponsor:  GlaxoSmithKline – ViiV  Protocol:  ING112574
Title:  A Phase III study to demonstrate the antiviral activity and safety of dolutegravir in HIV-1-infected adult subjects with treatment failure on an integrase inhibitor containing regimen (VIKING3)
04/11-06/13                   Study Closed
                                    Sponsor:  Tobira Therapeutics  Protocol:  TBR652-2-202
Title:  A Phase 2b Randomized, Double-Blind, Double-Dummy Trial of 100 or 200 mg Once-Daily Doses of Cenicriviroc (CVC, TBR-652) or Once-Daily EFV, Each With Open- Label FTC/TDF, in HIV-1-Infected, Antiretroviral Treatment-Naïve, Adult Patients With Only CCR5-Tropic Virus
04/11-Current               Enrollment Closed
                                    Sponsor:  Gilead Sciences  Protocol:  GS-US-236-0118
Title:  A Phase 3 Open-label Safety Study of Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients with Mild to Moderate Renal Impairment
03/11-03/14                   Study Closed
                                    Sponsor:  GlaxoSmithKline – ViiV  Protocol:  ING114467
Title:  A Phase III, randomized, study of the safety and efficacy of
GSK1349572 plus abacavir-lamivudine fixed-dose combination therapy administered once daily compared to Atripla over 96 weeks in HIV-1 infected antiretroviral therapy naive adult subjects (SINGLE)
02/11-09/13                   Study Closed
                                    Sponsor:  Gilead Sciences  Protocol:  GS-US-264-0110
Title:  A Phase 3B, Randomized, Open-label Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared with a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults
11/10-06/12                   Study Closed
                                    Sponsor:  Gilead Sciences  Protocol:  GS-US-264-0106
Title:  A Phase 3 Randomized, Open-Label Study to Evaluate Switching from Regimens Consisting of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors to Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF) Fixed-dose Regimen in Virologically-Suppressed, HIV-1 Infected Patients
11/10-02/14                   Study Closed
                                    Sponsor:  GlaxoSmithKline – ViiV  Protocol:  ING111762
Title:  A Phase III Randomized, Double-blind Study of the Safety and Efficacy of GSK1349572 50 mg Once Daily Versus Raltegravir 400 mg Twice Daily, Both Administered with an Investigator-selected Background Regimen Over 48 Weeks in HIV-1 Infected, Integrase Inhibitor-Naïve, Antiretroviral Therapy-Experienced Adults (SAILING)
11/10-02/14                   Study Closed
                                    Sponsor:  GlaxoSmithKline – ViiV  Protocol:  ING113086
Title:  A Phase III, randomized, double-blind study of the safety and efficacy of GSK1349572 50 mg once daily to raltegravir 400 mg twice daily both administered with fixed-dose dual nucleoside reverse transcriptase inhibitor  therapy over 96 weeks in HIV-1 infected antiretroviral therapy naïve adult subjects (SPRING2)
09/10-04/11                   Study Closed
                                    Sponsor:  GlaxoSmithKline – ViiV  Protocol:  SGN113399
Title:  A Phase 2b study to select a once daily oral dose of GSK2248761 in HIV-1 infected antiretroviral therapy-experienced adults with non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance (SONNET)
05/10-02/12                   Study Closed
                                    Sponsor:  GlaxoSmithKline – ViiV  Protocol:  EPZ113734
Title:  A Prospective, Randomized, Multicenter, Open-Label Study to Compare the Efficacy and Safety of Simplifying from a Regimen of Atazanavir + Ritonavir + Tenofovir/Emtricitabine to Atazanavir + Abacavir/Lamivudine Without Ritonavir for 48 Weeks in Virologically Suppressed, HIV-1 Infected, HLAB* 5701 Negative Subjects (ASSURE)
04/10-Current               Enrollment Closed
                                    Sponsor:  Gilead Sciences  Protocol:  GS-US-216-0114
Title:  A Phase 3, Randomized, Double-Blind, Study to Evaluate the Safety and Efficacy of GS-9350-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered with Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults (ATZ/GS-9350 vs ATZ/r + TVD each)
04/10-11/13                   Study Closed
                                    Sponsor:   Gilead Sciences  Protocol:  GS-US-236-0103
Title:  A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naїve Adults
03/10-09/14                   Study Closed
                                    Sponsor:  Gilead Sciences  Protocol:  GS-US-236-0102
Title:  A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 Versus Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naїve Adults
11/09-06/14                   Study Closed
                                    PI-IND 106686
                                    Investigator sponsored  Protocol – Continued use of Ibalizumab (TNX 355, Hu5AB)
                                    Intravenous injection.
10/09-01/13                   Study Closed
Sponsor:  Tibotec Therapeutics  Protocol: TMC125HIV4007
Title:  A Multicenter, Single-Arm, Open-Label, Study of the Once Daily Combination of Etravirine and Darunavir/ritonavir as Dual-Therapy in Early Treatment-Experienced Patients (INROADS)
08/09-04/11                   Sub-Investigator
Sponsor:  Napo – Salix Pharmaceuticals  Protocol: NP303-101
Title:  Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Two-Stage Study to Assess the Efficacy and Safety of Crofelemer 125 mg, 250 mg, and 500 mg Orally Twice Daily for the Treatment of HIV-Associated Diarrhea (ADVENT Trial)
01/09-05/14                   Study Closed
                                    Sponsor:  Tibotec Therapeutics  Protocol:  TMC114HIV3015
                                    Title: A Single Arm, Open Label Study to Assess the Pharmacokinetics of Darunavir/Ritonavir and/or Etravirine in HIV-1 Infected Pregnant Women
11/08-01/11                   Study Closed
                                    Sponsor:  Pfizer  Protocol:  A4001080
                                    Title:  A Multicenter, Randomized, Open, Comparative Trial of Maraviroc Versus Etravirine Each in Combination with Darunavir/Ritonavir and Raltegravir for the Treatment of Antiretroviral-Experienced HIV-1 Subjects Co-Infected with Hepatitis C and/or Hepatitis
08/08-04/10                   Study Closed
                                    Sponsor: Howard Hughes Med Institute-Exchange Acct
                                    Protocol: 2003-P-001678/55;MGH
                                    Title: HIV Elite Controller Study
                                  
08/08- Current              Enrollment Closed
                                    Sponsor: Gilead Sciences  Protocol: GS-US-183-0145 Phase 3
                                    Title: A Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Ritonavir-Boosted  Elvitegravir (EVG/r) Versus Raltegravir (RAL) Each Administered With a Background Regimen in HIV 1 Infected   Antiretroviral Treatment-Experienced Adults
07/08-03/11                   Study Closed
                                    Sponsor: Gilead Sciences  Protocol: GS-US-164-0216 Phase IV
                                    Title: The Swift Study: A Prospective, Randomized, Open Label Phase IV Study to Evaluate the Rationale of Switching from Fixed Dose Abacavir (ABC)/Lamivudine (3TC) to Fixed Dose Tenofovir DF (TDF)/Emtricitabine (FTC) in Virologically Suppressed, HIV 1 Infected Patients Maintained on a Ritonavir-Boosted Protease Inhibitor Containing Antiretroviral Regimen
05/08-Current               Enrollment Closed
                                    Sponsor: Pfizer Inc  Protocol: A4001067
Title: An International, Multicenter, Prospective ObservationalStudy Of The Safety Of Maraviroc Used With Optimized Background Therapy In Treatment-Experienced HIV-1 Infected Patients     
04/08-11/10                   Study Closed
                                    Sponsor: Abbott Laboratories  Protocol: M10-336
                                    Title: A Randomized, Open- label, Study of Lopinavir/ritonavir 400/100 mg Tablet Twice- Daily + Co-formulated Emtricitabine/Tenofovir Disoproxil Fumarate 200/300 mg Once-Daily Versus Lopinavir/ritonavir 400/100mg Tablet Twice-Daily + Raltegravir 400 mg Twice Daily in Antiretroviral Naïve, HIV-1 Infected Subjects
01/08-04/11                   Study Closed
                                    Sponsor:  TaiMed Biologics, Inc.  Protocol:  TMB-202 A Phase 2b
Title: A Phase 2b, Randomized, Double-Blinded, 48 Week, Multicenter, Placebo-Controlled, Dose-Optimizing Study of Ibalizumab Plus an Optimized Background Regimen Versus Placebo Plus an Optimized Background Regimen in Treatment- Experienced Patients Infected With HIV-1
05/07-12/08                   Study Closed
                                    Sponsor:  Roche Laboratories Inc.  Protocol:  ML20837
Title:  A Multicenter, Open-label Study Evaluating the Antiviral Activity and Safety of Enfuvirtide (ENF) Once Daily (QD) or Twice Daily (BID) in Triple-class Experienced HIV-1 Infected Patients Changing Their Therapy to a Standard of Care (SOC) Regimen That Includes Initiating an Integrase Inhibitor (in EAP) plus an Optimized Background (OB) Antiviral Regimen (AMICI Study).
03/07-01/09                   Study Closed
                                    Sponsor:  Tibotec Therapeutics  Protocol:  TMC114HIV3004
Title:  An Open-label, Multicenter Trial to Compare the Efficacy, Safety, and Tolerability of Prezista/r by Gender and Race, When Administered in Combination With an Individually Optimized Background Regimen Over a 48 Week Treatment Period.
03/07-01/08                   Study Closed
                                    Sponsor:  Pfizer Inc.      Protocol:  A001050
Title:  A Multi-center, Open-Label, Expanded Access Trial of Maraviroc.
02/07-05/10                   Study Closed
                                    Sponsor:  GlaxoSmithKline, Inc.  Protocol:  EPZ108859
Title:  Safety and Efficacy of an Initial Regimen of Atazanavir + Ritonavir + the Abacavir/Lamivudine Fixed-Dose Combination Tablet for 36 Weeks Followed by Simplification to Atazanavir with the Abacavir/Lamivudine Fixed-Dose Combination Tablet or Maintenance of the Initial Regimen for an Additional 48 Weeks in Antiretroviral-Naïve HIV-1 Infected HLA-B*5701 Negative Subjects.
10/06-05/08                   Study Closed
                                    Sponsor:  Merck & Co., Inc.  Protocol:  023-00 MK-0518
Title:  Early Access of MK-0518 in Combination With an Optimized Background Antiretroviral Therapy (OBT) in Highly Treatment Experienced HIV-1 Infected Patients With Limited to No Treatment Options.           
08/06-09/08                   Study Closed
                                    Sponsor:  Tibotec Pharmaceuticals. Ltd.  Protocol:  TMC125-C214
                                    Title:  Early Access of TMC125 in Combination With Other Antiretrovirals in Treatment-Experienced HIV-1 Infected Subjects with Limited Treatment Options.
07/06-11/07                   Study Closed
                                    Sponsor:  Bristol-Myers Squibb & Gilead Sciences  Protocol:  AI226073
                                    Title:  A Phase IV, Open-label, Randomized, Multicenter Study Evaluating Efficacy and Tolerability of Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir DF Compared to Unmodified HAART in HIV-1 Infected Subjects Who Have Achieved Virological Suppression on their HAART Regimen.
06/06-09/08                   Study Closed
                                    Sponsor:  Abbott  Laboratories  Protocol:  M06-802
                                    Title:  A Phase 3, Randomized, Open-label Study of Lopinavir/ritonavir Tablets 800/200 mg Once-daily Versus 400/100 mg Twice-daily when Coadministered with Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-experience, HIV-1 Infected Subjects.
06/06-10/06                   Study Closed
                                    Sponsor:  Trimeris, Inc.  Protocol:  ENF-407/ML 19849
                                    Title:  Biojector 2000 Open-Label Safety Study (BOSS).  
04/06-06/07                   Study Closed
                                    Sponsor:  Roche Laboratories Inc.  Protocol:  ML19712              
                                    Title:  A Multicenter, Open-Label Study Evaluating The Safety and Efficacy Of A New Investigational Protease Inhibitor (PI) With Fuzeon (Enfuvirtide) Plus Background Antiretroviral Regimen in HIV-1 Infected, Triple-Class Treatment-Experienced Patients (BLQ).
04/06-04/08                   Study Closed
                                    Sponsor:  GlaxoSmithKline, Inc.  Protocol:  EPZ104057
                                    Title:  A 96-Week, Phase IV, Randomized, Double-Blind, Multicenter Study of the Safety and Efficacy of Epzicom Versus Truvada Administered in Combination with Kaletra in Antiretroviral-Naïve HIV-1 Infected Subjects.
01/06-09/08                   Study Closed
                                    Sponsor:  Abbott  Laboratories  Protocol:  M05-730
                                    Title:  A Phase 3, Randomized, Open-label, Study of Lopinavir/ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, When Co-administered with NRTIs in Antiretroviral Naïve HIV-1 Infected Subjects.
10/05-08/06                   Study Closed
                                    Sponsor:  Tibotec Pharmaceuticals Ltd.  Protocol:  TMC114-C226
                                    Title:  Early Access of TMC114 In Combination With Low-Dose Ritonavir (RTV) and Other Antiretrovirals (ARVS) In Highly Treatment Experienced HIV-1 Infected Subjects With Limited To No Treatment Options.                                
12/04-4/05                     Study Closed
                                    Sponsor:  GlaxoSmithKline, Inc.  Protocol:  ESS101822 Phase IIIB
                                    Title:      A Phase IIIB, Randomized, Open-Label, Multicenter, Parallel-Arm Study to Evaluate the Short-Term Safety and Tolerability of Abacavir/Lamivudine Fixed-Dose Combination Tablet Administered Once-Daily or the Separate Abacavir and Lamivudine Tablets Administered Twice-Daily, as Part of a Three or Four-Drug Regimen, in Antiretroviral-Naïve HIV-1 infected subjects.
12/04-4/05                    Study Closed
                                    Sponsor:  Roche Laboratories  Protocol:  ML18018D Phase IV
                                    Title:      A 12 week, prospective, open-label, multicenter, cohort study to assess HIV-Patient Quality of Life and Tolerability after Administration of Enfuvirtide-containing HAART – QUALITY Study.
11/04-08/05                  Study Closed
                                    Sponsor:  Gilead Sciences  Protocol:  GS-US-164-0107Phase IV
                                    Title:      Combination of Efavirenz and Truvada (The COMET Study): A Phase 4 Evaluation of Switching from Twice Daily Zidovudine and Lamivudine (Combivir) to a Simplified, Once-Daily Regimen of Co-formulated Emtricitabine and Tenofovir Disoproxil Fumarate (Truvada), in Virologically Suppressed, HIV-infected Patients Taking Efavirenz.
09/04-10/09                   Study Closed
                                    Sponsor:  BMS Virology  Protocol:  A1424128 Phase IV
                                    Title:  A Phase IV, Multi-Center, Cross-Sectional Study To Evaluate the 150L Substitution Among Subjects Experiencing Virologic Failure On A HAART Regimen Containing Atazanavir (ATV).       
05/04-03/05                   Study Closed
                                    Sponsor:  Cubist Pharmaceuticals  Protocol:  DAP-4PSW-03-03 Phase IV
                                    Title:  Cubicin for Post-Surgical Wound Infections.
11/03-08/04                   Study Closed
                                    Sponsor:  Eli Lilly and Company  Protocol:  F1K-MC-EVCL
                                    Title:  Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients with Early Stage Severe Sepsis.
09/03-03/05                  Study Closed
                                    Sponsor:  Solvay Pharmaceuticals  Protocol:  S1752101 Phase II
                                    Title:  A Double-blind, Randomized, Parallel-group, Pilot study of Oral Dronabinol Versus Placebo in the Prevention of Highly Active Antiretroviral HAART) Related Nausea and Vomiting.
 

Considering a change in your HIV Therapy?

 

Protocol: TMB-202

 

Protocol:  A4001080

 

Protocol:  M10-336

 
 
 

Fort Pierce FL HIV & AIDs Treatment

Fort Pierce FL Hepatitis C Treatment, General ID & Clinical Trials

Call us at: (772) 595-9830
 
356 Midway Rd,
Fort Pierce, FL 34982